Lung cancer is the leading cause of cancer related deaths in United States, accounting for more than one-fourth of the deaths annually. Although comparatively rare and relatively less studied, genetic abnormalities other than EGFR mutations, ALK rearrangements and KRAS mutations account for significant proportion of the driver mutations identified thus far. The targeted agents against BRAF V600E mutation, MET pathway, ROS1 rearrangement, RET rearrangement and HER-2 pathways offer promising therapeutic options. Recruiting patients with these rarer mutations to well-designed, large multicenter trials to further validate the use of targeted agents remains a challenge. The clinical data and ongoing trials with these agents are reviewed in this article.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2016.
All research outputs
#17,778,101
of 22,834,308 outputs
Outputs from Expert Review of Anticancer Therapy
#695
of 1,053 outputs
Outputs of similar age
#267,845
of 393,728 outputs
Outputs of similar age from Expert Review of Anticancer Therapy
#17
of 35 outputs
Altmetric has tracked 22,834,308 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,053 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,728 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
